1. The protective effect of puerarin on MIN6 cell injury induced by palmitic acid
Ming CHEN ; Yu-Tong GAO ; Xiao-Lin ZHANG ; Ya-Ni WU ; Xiu-Sha WEI ; Hen-Bin HUANG ; Guang-Yan MO ; Xi YE ; Xiao-Hui XU ; Tao LIANG
Chinese Pharmacological Bulletin 2022;38(6):893-897
Aim To evaluate the effects of puerarin (PR) on pancreatic islet MIN6 cell injury and apopto- sis induced by palmitic acirl ( PA).Methods MIN6 cells pretreated with 2 h different concentrations of PR were then co-cultured with 120 (xmol • L"1 PA for 24 h to establish the cell injury and apoptosis model.MTT, LDH,MDA and GSH were used to determine the dam¬age of MIN6 cells.AOEB fluorescence staining was used to detect the apoptosis of MIN6 cells.Western blot was used to detect the expressions of inflammation- related protein NF-kB , apoptosis-related factors Bcl-2 and Bax.Results Compared with model group, cell viability and GSH activity of puerarin administration groups increased, LDH and MDA contents decreased.the protein expressions of p-NF-KB and Bax were down-regulated, and the protein expressions of Bcl-2 were up-regulated (P <0.05).Conclusions Puerar- in ean improve the function of pancreatic islet cells by inhibiting apoptosis and inflammation, and ameliorate pancreatic islet MIN6 cell injury and apoptosis induced by palmitic acid-induced, alleviate MIN6 cell injury in¬duced by inflammatory factors, which may be achieved by down-regulating the expression of p-NF-KB and Bax proteins,and up-regulating the expression of Bcl-2 pro¬tein.
2.Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial.
Xiaoyan TANG ; Dezheng CHEN ; Ling ZHANG ; Ping FU ; Yanxia CHEN ; Zhou XIAO ; Xiangcheng XIAO ; Weisheng PENG ; Li CHENG ; Yanmin ZHANG ; Hongbo LI ; Kehui LI ; Bizhen GOU ; Xin WU ; Qian YU ; Lijun JIAN ; Zaizhi ZHU ; Yu WEN ; Cheng LIU ; Hen XUE ; Hongyu ZHANG ; Xin HE ; Bin YAN ; Liping ZHONG ; Bin HUANG ; Mingying MAO
Journal of Zhejiang University. Science. B 2022;23(11):931-942
OBJECTIVES:
Safe and effective anticoagulation is essential for hemodialysis patients who are at high risk of bleeding. The purpose of this trial is to evaluate the effectiveness and safety of two-stage regional citrate anticoagulation (RCA) combined with sequential anticoagulation and standard calcium-containing dialysate in intermittent hemodialysis (IHD) treatment.
METHODS:
Patients at high risk of bleeding who underwent IHD from September 2019 to May 2021 were prospectively enrolled in 13 blood purification centers of nephrology departments, and were randomly divided into RCA group and saline flushing group. In the RCA group, 0.04 g/mL sodium citrate was infused from the start of the dialysis line during blood draining and at the venous expansion chamber. The sodium citrate was stopped after 3 h of dialysis, which was changed to sequential dialysis without anticoagulant. The hazard ratios for coagulation were according to baseline.
RESULTS:
A total of 159 patients and 208 sessions were enrolled, including RCA group (80 patients, 110 sessions) and saline flushing group (79 patients, 98 sessions). The incidence of severe coagulation events of extracorporeal circulation in the RCA group was significantly lower than that in the saline flushing group (3.64% vs. 20.41%, P<0.001). The survival time of the filter pipeline in the RCA group was significantly longer than that in the saline flushing group ((238.34±9.33) min vs. (221.73±34.10) min, P<0.001). The urea clearance index (Kt/V) in the RCA group was similar to that in the saline flushing group with no statistically significant difference (1.12±0.34 vs. 1.08±0.34, P=0.41).
CONCLUSIONS
Compared with saline flushing, the two-stage RCA combined with a sequential anticoagulation strategy significantly reduced extracorporeal circulation clotting events and prolonged the dialysis time without serious adverse events.
Humans
;
Citric Acid/adverse effects*
;
Prospective Studies
;
Sodium Citrate
;
Hemorrhage/chemically induced*
;
Citrates/adverse effects*
;
Anticoagulants/adverse effects*
;
Renal Dialysis/adverse effects*